Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 26, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tempus AI, Inc. ("Tempus AI" or the "Company") (NASDAQ: TEM) investors of a class action representing investors that bought securities between August 6, 2024 and May 27, 2025, inclusive (the "Class Period"). Tempus AI investors have until August 12, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Por ...

本报（chinatimes.net.cn）记者杨燕 北京报道 在四川大学的实验室里，看似普通的发酵罐中，正孕育着一场技术革命，四川大学轻工科学与工程学院 研究员秦久福和他的团队利用将微生物改造成高效"细胞工厂"的合成生物学技术，不断探索一种名为亚 精胺的天然分子的生产和应用方式。 亚精胺是一种人体内天然存在的多胺类物质，因其在抗衰老、心血管疾病预防等领域的广泛应用，又被 誉为"下一个千亿级生物活性分子"。然而，其高昂的生产成本长期制约着产业化进程。 秦久福和其团队通过多年的技术攻坚，不仅提升了亚精胺的合成效率，更通过与行业龙头之间的合作， 探索出一条从实验室到产业的"最后一公里"路径。 合成生物学如何破解"卡脖子"难题 亚精胺——这种人体内天然存在的多胺物质，近年来因抗衰老、神经保护等功效成为生物医药热点。作 为天然抗衰与神经保护活性分子，亚精胺在医药、食品、农业领域应用广阔，尤其在抗衰老领域，它作 为"细胞自噬"功能的关键物质，被《中国老年医学杂志》列为五大抗衰潜力成分之一。 但这样的"生物魔法"在国内长期受制于生产技术瓶颈，成本居高不下成为产业大规模应用亚精胺的桎梏 瓶颈，市场需求爆发与技术供给不足的矛盾 ...

Group 1 - The core objective is to focus on the '1+2+4+N' target task system to promote high-quality development and efficient governance in Zhoukou, aiming to contribute significantly to the construction of a national regional central port city [1][2] - The city plans to accelerate the development of a strong advanced manufacturing industry by nurturing strategic emerging industries such as biodegradable materials, biomedicine, and intelligent components, while upgrading traditional industries like textiles and special steel [1] - Zhoukou aims to enhance the digital transformation of enterprises, focusing on increasing the intelligence, sustainability, and profitability of the manufacturing sector through a structured approach [1] Group 2 - The construction of a port-type national logistics hub is prioritized, with a focus on developing the Zhoukou Port small collection operation area and dedicated railway lines to enhance modern, professional, and intelligent inland shipping [2] - The city intends to promote cultural prosperity by leveraging its status as a national historical and cultural city, aiming to develop a cultural tourism industry as a pillar of the local economy [2]

Core Insights - The Qingdao Traditional Chinese Medicine (TCM) Inheritance and Innovation Base project has successfully passed its completion inspection, showcasing a modern park dedicated to the mission of TCM inheritance and innovation [1] Group 1: Project Overview - The first phase of the Qingdao TCM Inheritance and Innovation Base project covers approximately 150 acres with a total construction area of about 150,000 square meters, consisting of 14 individual buildings that include various functional areas such as laboratories, research incubation buildings, and wellness centers [3] - The project is divided into two main sections: the west area focuses on research and incubation with a design inspired by Tai Chi and traditional Chinese elements, while the east area emphasizes medical and wellness services, incorporating classical garden design and traditional courtyard structures [3] Group 2: Facilities and Features - The experimental building A is spacious and well-lit, featuring areas for the cultivation and exhibition of traditional Chinese medicinal plants, as well as pilot workshops and animal laboratories for innovative experiments [5] - The research incubation building spans approximately 7,700 square meters and includes meeting rooms, offices, and a 400-person auditorium, while the research support building offers dining, conference, and accommodation facilities with a total area of about 20,000 square meters [7] - The wellness building provides a comfortable living environment with 116 wellness apartments and 162 beds for elderly care, along with transitional medical service areas for patients [7] Group 3: Collaboration and Future Plans - The project will collaborate with Shandong University of Traditional Chinese Medicine to establish a hospital that leverages expert resources to provide TCM diagnosis and treatment services for complex diseases, as well as preventive care and wellness services [9] - As a key construction project in Qingdao High-tech Zone, the TCM base aims to become a highland for marine TCM research and an innovation hub, integrating technology innovation, talent cultivation, and industry incubation to enhance TCM and wellness services for the local community [9]

Up to $40 Million Private Equity Financing into a New Entity Addressing Cardiac Genetic Diseases that Existing AAV Platforms are Unable to Treat Lexeo Contributing Expertise and Know-How in Cardiac Genetic Medicines, Preclinical Intellectual Property, and Technology, in Combination with Novel Non-Viral RNA Delivery Platform Represents Pipeline Diversification and Advancement of Leading-Edge Cardiovascular Science NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical ...

Core Viewpoint - Krystal Biotech, Inc. has initiated its Phase 3 clinical trial named "IOLITE" to evaluate KB803 for treating and preventing corneal abrasions in patients with dystrophic epidermolysis bullosa (DEB) [1][2] Group 1: Clinical Trial Details - IOLITE is a double-blind, multicenter, placebo-controlled study with a crossover design, focusing on KB803 administered as eye drops [4] - The trial will enroll approximately 16 subjects, with a primary endpoint measuring the change in average days per month with corneal abrasion symptoms while receiving KB803 versus placebo [5][6] - Patients must complete a 12-week run-in period in an ongoing natural history study before participating in IOLITE [4][5] Group 2: Patient Population and Disease Impact - Over 25% of DEB patients are believed to experience ocular complications, with more than 50% of patients suffering from the recessive form of DEB (RDEB) [2] - The estimated number of DEB patients in the U.S. exceeds 750, with over 2,000 affected globally [2] - Current management of DEB-related ocular complications is limited to supportive care and surgical interventions, with no corrective therapies available [2] Group 3: Previous Findings and Compassionate Use - A previous compassionate use case of KB803 demonstrated full corneal healing at three months and significant visual acuity improvement from hand motion to 20/25 by eight months [1][12] - The compassionate use case involved a patient with severe cicatrizing conjunctivitis secondary to DEB, treated with regular B-VEC administration [11][12] Group 4: Company Overview - Krystal Biotech, Inc. is a global biotechnology company focused on developing genetic medicines for diseases with high unmet medical needs [13] - The company’s first commercial product, VYJUVEK®, is the first-ever redosable gene therapy approved by the FDA and EMA for treating dystrophic epidermolysis bullosa [13]

中证报中证网讯(记者李梦扬)近日，"2025上海财经大学商学院MBA/EMBA'商链共生'校企合作及培养 方向升级发布会"在上海财经大学科技园国际会议中心举行。活动聚焦产教融合新生态与商科人才培养 创新，发布全新校企合作计划、培养方向升级方案、2026级新生奖学金方案和招生政策。 随后，上海财经大学商学院副院长孙琦重磅发布"商链共生"校企合作计划及2026级MBA/EMBA全新班 型和培养方向。该计划以"时代之困、产业之痛、教育之变"为切入点，推出以前沿讲座论坛、深度产业 园区参访、业界与学界专家"双师同堂"、走进企业的"移动课堂"、解决企业真实问题的"整合实践"项目 等为例的七大模块协同推进产教融合。 此外，发布会现场举行了校企合作授牌仪式。南通高新技术产业开发区、嘉定工业互联网产业园、国科 长三角资本管理有限公司、上海脉策数据科技有限公司、浙江纳美新材料料股份有限公司、上海林清轩 生物科技股份有限公司、哈尔滨市康隆药业有限责任公司、济川药业（600566）嘉泽创投有限公司、苏 州世名科技（300522）股份有限公司等9家单位被授予"MBA人才培养实践基地"，覆盖人工智能、生物 医药、工业互联网等前沿领域， ...

在提升科技企业服务水平方面，广东全面落实高新技术企业税收减免、企业研发费用税前加计扣除等优惠政策，2024年，全省企业享受研发费用税前加计扣 除金额超6900亿元。 此外，广东以应用场景为抓手，深入拓展人工智能与机器人、新型储能、新能源汽车、低空经济、商业航天、生物医药等新兴产业发展空间。2024年，智能 机器人产业集群营业收入超900亿元，整体实力处于国内第一梯队。广东还积极推动未来产业发展，聚焦量子科技、通用智能、生物制造等未来产业领域进 行前瞻布局，实施一批攻关项目，下好先手棋、占据好位势。 杨惠芳介绍，广东省区域创新综合能力连续8年居全国首位，"深圳—香港—广州"科技集群连续5年位列全球创新指数第二位，广东全省研发经费投入突破 5100亿元继续领跑全国，研发投入强度达到3.6%，研发经费投入、研发人员、高新技术企业、发明专利有效量、PCT国际专利申请量等主要科技指标均保持 全国首位，有力支撑粤港澳大湾区国际科技创新中心和具有全球影响力的产业科技创新中心建设不断取得新进展新成效。 6月23日，在2025年"活力中国调研行"广东主题采访情况介绍会上，广东省科技厅二级巡视员杨惠芳表示，广东推动企业在科技创新 ...

Hims & Hers Health shares rocketed higher over the last year, rewarding investors.When it comes to healthcare stocks, many investors pay attention to the usual suspects: Eli Lilly, Novo Nordisk, CVS Health, or Johnson & Johnson. These companies have built up enormous brand equity thanks to blockbuster drugs and widely recognized pharmacy management services.With the exception of CVS, whose shares have risen 46% so far this year, none of the other companies have generated robust stock price returns so far in ...

Core Insights - Adia Nutrition, Inc. has received full approval from the Agency for Health Care Administration (AHCA) for its clinic, Adia Med of Winter Park, allowing it to accept insurance for treatments [2][4][5] - This approval positions Adia Med as a leading provider of innovative therapies, including Autologous Hematopoietic Stem Cell Transplantation (aHSCT) for Multiple Sclerosis and other autoimmune conditions [4][6] - The clinic aims to enhance patient access to life-changing treatments by advocating for insurance coverage, thereby reducing financial barriers [5][6] Company Overview - Adia Nutrition, Inc. is a publicly traded company focused on revolutionizing healthcare through innovative regenerative medicine and nutritional supplements [7] - The company operates two main divisions: a supplement division offering premium organic supplements and a medical division specializing in advanced stem cell therapies [7] - Adia Med of Winter Park opened in January 2025 and is designed to provide personalized regenerative treatments [6][7] Market Context - The approval by AHCA allows Adia Nutrition to enter the $4.9 trillion healthcare insurance market, enhancing its growth potential [6] - By accepting insurance, the company can better serve patients and expand its reach within the healthcare sector [5][6]